1. |
张缪佳. 加强对结缔组织病相关肺动脉高压的预后评估. 中华风湿病学杂志, 2012, 16(8): 505-507.
|
2. |
McLaughlin V, Channick RN, Ghofrani HA, et al. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension. Eur Respir J, 2015, 46(2): 405-413.
|
3. |
孔祥萦, 陆凤霞, 周洁, 等. 西地那非联合波生坦治疗儿童先心病合并肺动脉高压的临床研究. 南京医科大学学报(自然科学版), 2017, 37(7): 861-864.
|
4. |
Dabiri G, Falanga V. Connective tissue ulcers. J Tissue Viability, 2013, 22(4): 92-102.
|
5. |
钱凤文, 陈利明. 超声心动图新技术在评价肺动脉高压患者右心功能中的应用进展. 中国呼吸与危重监护杂志, 2013, 12(4): 427-429.
|
6. |
Roberts JD, Forfia PR. Diagnosis and assessment of pulmonary vascular disease by Doppler echocardiography . Pulm Circ, 2011, 1(2): 160-181.
|
7. |
顾睛, 何建国. 2009年欧美肺动脉高压指南解读与比较.中华医学杂志, 2010, 90(20): 1378-1380.
|
8. |
Fishman AP. Primary pulmonary arterial hypertension: a look back. J Am Coll Cardiol, 2004, 43(12): 2S-4S.
|
9. |
Butrous G. The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. Glob Cardiol Sci Pract , 2014, 2014(3): 257-290.
|
10. |
Lajoie AC, Bonnet S, Provencher S. Combination therapy in pulmonary arterial hypertension: recent accomplishments and future challenges. Pulm Circ, 2017, 7(2): 312-325.
|
11. |
曾小峰. 结缔组织病相关肺动脉高压-风湿病的新挑战. 中华风湿病学杂志, 2010, 14(2): 73-75.
|
12. |
张成, 何建国, 卢献灵, 等. 口服西地那非治疗肺动脉高压的效果和安全性初步研究. 中华医学杂志, 2011, 91(6): 370-374.
|
13. |
Wang RC, Jiang FM, Zheng QL, et al. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systemaic review. Respir Med, 2014, 108(3): 531-537.
|
14. |
Benza RL, Miller DP, Barst RJ, et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest, 2012, 142(2): 448-456.
|
15. |
Sompradeekul S, Wattanasiriphakdee S. Hemodynamic effect of iloprost inhalation and oral sildenafil during acute vasoreactivity test in pulmonary arterial hypertension. J Med Assoc Thai, 2015, 98(2): 144-149.
|
16. |
Baptista R, Castro G, Dasilva AM, et al. Long-term effect of bosentan in pulmonary hypertension associated with complex congenital heart disease. Rev Port Cardiol, 2013, 32(2): 123-129.
|